Ann Pediatr Endocrinol Metab.  2022 Mar;27(1):15-21. 10.6065/apem.2142236.118.

Endocrinal dysfunction in children with Down syndrome

• Metwalley KA
• Farghaly HS

• KMID: 2528193
• DOI: http://doi.org/10.6065/apem.2142236.118

Abstract

Down syndrome (DS) is the most common genetic disorder in live-born infants. Children with DS are at increased risk of numerous endocrinal comorbidities. The information contained in this article will provide pediatricians with a narrative overview of different presentations, diagnoses, and management recommendations of various endocrinal disorders in children with DS. We systematically searched PubMed, Embase, Google Scholar, MEDLINE, EBSCO, and Science Direct, and potentially relevant articles were identified and retrieved from electronic and print journals.

Keyword

Down syndrome; Hypothyroidism; Obesity; Short stature

Reference

References

1. Guaraldi F, Rossetto Giaccherino R, Lanfranco F, Motta G, Gori D, Arvat E, et al. Endocrine autoimmunity in Down’s syndrome. Front Horm Res. 2017; 48:133–46.

2. Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. Eur J Pediatr. 2010; 169:1445–52.

3. Lagan N, Huggard D, Mc Grane F, Leahy TR, Franklin O, Roche E, et al. Multiorgan involvement and management in children with Down syndrome. Acta Paediatr. 2020; 109:1096–111.

4. Bull ML. Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011; 128:393–406.

5. Fort P, Lifshitz F, Bellisario R, Davis J, Lanes R, Pugliese M, et al. Abnormalities of thyroid function in infants with Down syndrome. J Pediatr. 1984; 104:545–9.

6. Graber E, Chacko E, Regelmann MO, Costin G, Rapaport R. Down syndrome and thyroid function. Endocrinol Metab Clin North Am. 2012; 41:735–45.

7. Moosa S, Segal DG, Christianson AL, Gregersen NE. Thyroid dysfunction in a cohort of South African children with Down syndrome. S Afr Med J. 2013; 103:966–70.

8. Kluesner JK, Beckman DJ, Tate JM, Beauvais AA, Kravchenko MI, Wardian JL, et al. Analysis of current thyroid function test ordering practices. J Eval Clin Pract. 2018; 24:347–52.

9. Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. JAMA. 2019; 322:153–60.

10. American Academy of Pediatrics Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011; 128:393–406.

11. Van Cleve S, Cohen W. Part I: clinical practice guidelines with Down syndrome from birth to 12 years. J Pediatr Health Care. 2006; 20:47–54.

12. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Anneren G. Thyroid dysfunction in Down’s syndrome: relation to age and thyroid autoimmunity. Arch Dis Child. 1998; 79:242–45.

13. Pierce MJ, LaFranchi SH, Pinter JD. Characterization of thyroid abnormalities in a large cohort of children with Down syndrome. Horm Res Paediatr. 2017; 87:170–8.

14. King K, O’Gorman C, Gallagher S. Thyroid dysfunction in children with Down syndrome: a literature review. Ir J Med Sci. 2014; 183:1–6.

15. Kennedy RL, Jones TH, Cuckle HS. Down's syndrome and the thyroid. Clin Endocrinol (Oxf). 1992; 37:471–76.

16. Van Trotsenburg ASP, Vulsma T, van Santen HM, Cheung W, de Vijlder JJM. Lower neonatal screening thyroxine concentrations in Down syndrome newborns. J Clin Endocrinol Metab. 2003; 88:1512–5.

17. Cutler AT, Benezra-Obeiter R, Brink SJ. Thyroid function in young children with Down syndrome. Am J Dis Child. 1986; 140:479–83.

18. Graber E, Chacko E, Regelmann MO, Costin G, Rapaport R. Down syndrome and thyroid function. Endocrinol Metab Clin North Am. 2012; 41:735–45.

19. Fernhoff PM, Brown AL, Elsas LJ. Congenital hypothyroidism: increased risk of neonatal morbidity results in delayed treatment. Lancet. 1987; 1:490–1.

20. Cebeci AN, Güven A, Yıldız M. Profile of hypothyroidism in Down's syndrome. J Clin Res Pediatr Endocrinol. 2013; 5:116–20.

21. Gibson PA. Longitudinal study of thyroid function in Down’s syndrome in the first two decades. Arch Dis Child. 2005; 90:574–8.

22. Prasher V, Ninan S, Haque S. Fifteen-year follow-up of thyroid status in adults with Down syndrome. J Intellect Disabil Res. 2011; 55:392–6.

23. Tuysuz B, Beker DB. Thyroid dysfunction in children with Down’s syndrome. Acta Paediatr. 2001; 90:1389–93.

24. Luton D, Azria E, Polak M, Carre A, Vuillard E, Delezoide AL, et al. Thyroid function in fetuses with down syndrome. Horm Res Paediatr. 2012; 78:88–93.

25. Claret C, Goday A, Benaiges D, Chillarón JJ, Flores JA, Hernandez E, et al. Subclinical hypothyroidism in the first years of life in patients with Down syndrome. Pediatr Res. 2013; 73:674–8.

26. Iughetti L, Predieri B, Bruzzi P, Predieri F, Vellani G, Madeo SF, et al. Ten-year longitudinal study of thyroid function in children with Down's syndrome. Horm Res Paediatr. 2014; 82:113–21.

27. Roizen NJ, Magyar CI, Kuschner ES, Sulkes SB, Druschel C, van Wijngaarden E, et al. A community cross-sectional survey of medical problems in 440 children with Down syndrome in New York State. J Pediatr. 2014; 164:871–5.

28. Prasher V, Haque MS. Misdiagnosis of thyroid disorders in down syndrome: time to reexamine the myth? Am J Ment Retard. 2005; 110:23–7.

29. Sharav T, Collins RM, Baab PJ. Growth studies in infants and children with Down’s syndrome and elevated levels of thyrotropin. Am J Dis Child. 1988; 142:1302–6.

30. Amr NH. Thyroid disorders in subjects with Down syndrome: an update. Acta Biomed. 2018; 89:132–9.

31. Pueschel SM, Pezzullo JC. Thyroid dysfunction in Down syndrome. Am J Dis Child. 1985; 139:636–9.

32. Aversa T, Salerno M, Radetti G, Faienza MF, Iughetti L, Corrias A, et al. Peculiarities of presentation and evolution over time of Hashimoto's thyroiditis in children and adolescents with Down's syndrome. Hormones. 2015; 14:410–16.

33. De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, et al. Peculiarities of Graves' disease in children and adolescents with Down's syndrome. Eur J Endocrinol. 2010; 162:591–5.

34. Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, Cano-Pérez JF. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol (Oxf). 2009; 71:110–4.

35. Aversa T, Valenzise M, Salerno M, Corrias A, Iughetti L, Radetti G, et al. Metamorphic thyroid autoimmunity in Down syndrome: from Hashimoto's thyroiditis to Graves’ disease and beyond. Ital J Pediatr. 2015; 41:87.

36. Jeremiah DE, Leyshon GE, Rose T, Francis HW, Elliott RW. Down's syndrome and diabetes. Psychol Med. 1973; 3:455–7.

37. Ohyama Y, Utsugi T, Uchiyama T, Hanaoka T, Tomono S, Kurabayashi M. Prevalence of diabetes in adult patients with Down's syndrome living in a residential home. Diabetes Care. 2000; 23:705–6.

38. Rohrer TR, Hennes P, Thon A, Dost A, Grabert M, Rami B, et al. Down's syndrome in diabetic patients aged <20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes. Diabetologia. 2010; 53:1070–5.

39. Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia. 2006; 49:1179–82.

40. Mortimer GL, Gillespie KM. Early onset of autoimmune diabetes in children with Down syndrome-two separate aetiologies or an immune system pre-programmed for autoimmunity? Curr Diab Rep. 2020; 20:47.

41. Gillespie KM, Dix RJ, Williams AJ, Newton R, Robinson ZF, Bingley PJ, et al. Islet autoimmunity in children with Down's syndrome. Diabetes. 2006; 55:3185–8.

42. Aitken RJ, Mehers KL, Williams AJ, Brown J, Bingley PJ, Holl RW, et al. Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care. 2013; 36:1181–5.

43. Johnson MB, De Franco E, Greeley SAW, Letourneau LR, Gillespie KM; International DS-PNDM Consortium, et al. Trisomy 21 is a cause of permanent neonatal diabetes that is autoimmune but not HLA associated. Diabetes. 2019; 68:1528–35.

44. Dittmar M, Kahaly GJ. Immunoregulatory and susceptibility genes in thyroid and polyglandular autoimmunity. Thyroid. 2005; 15:239–50.

45. Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med. 1998; 15:160–3.

46. Butler AE, Sacks W, Rizza RA, Butler PC. Down syndrome-associated diabetes is not due to a congenital deficiency in β cells. J Endocr Soc. 2017; 1:39–45.

47. Kota SK, Tripathy PR, Kota SK, Jammula S. Type 2 diabetes mellitus: an unusual association with Down's syndrome. Indian J Hum Genet. 2013; 19:358–9.

48. Fonseca CT, Amaral DM, Ribeiro MG, Beserra IC, Guimarães MM. Insulin resistance in adolescents with Down syndrome: a cross-sectional study. BMC Endocr Disord. 2005; 5:6.

49. Onge ES, Miller SA, Motycka C, DeBerry A. A review of the treatment of type 2 diabetes in children. J Pediatr Pharmacol Ther. 2015; 20:4–16.

50. Arnell H, Gustafsson J, Ivarsson SA, Annerén G. Growth and pubertal development in Down syndrome. Acta Paediatr. 1996; 85:1102–6.

51. Piro E, Pennino C, Cammarata M, Corsello G, Grenci A, Lo Giudice C, et al. Growth charts of Down syndrome in Sicily: evaluation of 382 children 0-14 years of age. Am J Med Genet Suppl. 1990; 7:66–70.

52. Bertapelli F, Martin JE, Goncalves EM, de Oliveira Barbeta VJ, Guerra-Júnior G. Growth curves in down syndrome: implications for clinical practice. Am J Med Genet A. 2014; 164A:844–7.

53. Castells S, Beaulieu I, Torrado C, Wisniewski KE, Zarny S, Gelato MC. Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation. J Intellect Disabil Res. 1996; 40:509–17.

54. Annerén G, Gustavson KH, Sara VR, Tuvemo T. Growth retardation in Down syndrome in relation to insulin-like growth factors and growth hormone. Am J Med Genet Suppl. 1990; 7:59–62.

55. Van Gameren-Oosterom HB, Van Dommelen P, Oudesluys-Murphy AM, Buitendijk SE, Van Buuren S, Van Wouwe JP. Healthy growth in children with Down syndrome. PLoS One. 2012; 7:e31079.

56. Annerén G, Gustafsson J, Sara VR, Tuvemo T. Normalized growth velocity in children with Down's syndrome during growth hormone therapy. J Intellect Disabil Res. 1993; 37(Pt 4):381–7.

57. Annerén G, Tuvemo T, Carlsson-Skwirut C, Lönnerholm T, Bang P, Sara VR, et al. Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development. Arch Dis Child. 1999; 80:334–8.

58. Blethen SL. Leukemia in children treated with growth hormone. Trends Endocrinol Metab. 1998; 9:367–70.

59. Polidori N, Castorani V, Mohn A, Chiarelli F. Deciphering short stature in children. Ann Pediatr Endocrinol Metab. 2020; 25:69–79.

60. Bertapelli F, Pitetti K, Agiovlasitis S, Guerra-Junior G. Overweight and obesity in children and adolescents with Down syndrome-prevalence, determinants, consequences, and interventions: a literature review. Res Dev Disabil. 2016; 57:181–92.

61. van Gameren-Oosterom HB, van Dommelen P, Schönbeck Y, Oudesluys-Murphy AM, van Wouwe JP, Buitendijk SE. Prevalence of overweight in Dutch children with Down syndrome. Pediatrics. 2012; 130:e1520–6.

62. Murray J, Ryan-Krause P. Obesity in children with Down syndrome: background and recommend ations for management. Pediatr Nurs. 2010; 36:314–9.

63. Basil JS, Santoro SL, Martin LJ, Healy KW, Chini BA, Saal HM. Retrospective study of obesity in children with Down syndrome. J Pediatr. 2016; 173:143–8.

64. Artioli T. Understanding obesity in Down’s syndrome children. J Obes Metab. 2017; 1:1–3.

65. Stagi S, Lapi E, Romano S, Bargiacchi S, Brambilla A, Giglio S, et al. Determinants of vitamin d levels in children and adolescents with down syndrome. Int J Endocrinol. 2015; 2015:896758.

66. Sakadamis A, Angelopoulou N, Matziari C, Papameletiou V, Souftas V. Bone mass, gonadal function and biochemical assessment in young men with trisomy 21. Eur J Obstet Gynecol Reprod Biol. 2002; 100:208–12.

67. Fowler TW, McKelvey KD, Akel NS, Vander Schilden J, Bacon AW, Bracey JW, et al. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment. PLoS One. 2012; 7:e42967.

68. Kao CH, Chen CC, Wang SJ, Yeh SH. Bone mineral density in children with Down's syndrome detected by dual photon absorptiometry. Nucl Med Commun. 1992; 13:773–5.

69. Carfì A, Liperoti R, Fusco D, Giovannini S, Brandi V, Vetrano DL, et al. Bone mineral density in adults with Down syndrome. Osteoporos Int. 2017; 28:2929–34.

70. McKelvey KD, Fowler TW, Akel NS, Kelsay JA, Gaddy D, Wenger GR, et al. Low bone turnover and low bone density in a cohort of adults with Down syndrome. Osteoporos Int. 2013; 24:1333–8.

71. Wu J. Bone mass and density in preadolescent boys with and without Down syndrome. Osteoporos Int. 2013; 24:2847–54.

72. Mercer ES, Broecker B, Smith EA, Kirsch AJ, Scherz HC, A Massad C. Urological manifestations of Down syndrome. J Urol. 2004; 171:1250–3.

73. Chew G, Hutson JM. Incidence of cryptorchidism and ascending testes in trisomy 21: a 10 year retrospective review. Pediatr Surg Int. 2004; 20:744–7.

74. Brouwers MM, de Bruijne LM, de Gier RP, Zielhuis GA, Feitz WF, Roeleveld N. Risk factors for undescended testis. J Pediatr Urol. 2012; 8:59–66.

75. Dada R, Kumar R, Kucheria K. A 2-year-old baby with Downs syndrome, cryptorchidism and testicular tumour. Eur J Med Genet. 2006; 49:265–8.

76. Ichiyanagi O, Sasagawa I, Kubota Y, Yaguchi H, Suzuki Y, Nakada T. Down's syndrome associated with seminoma in undescended testis. Scand J Urol Nephrol. 1998; 32:365–7.

77. Hasen J, Boyar RM, Shapiro LR. Gonadal function in trisomy 21. Horm Res. 1980; 12:345–50.

78. Attia AM, Ghanayem NM, El Naqeeb HH. Sexual and reproductive functions in men with Down's syndrome. Menoufia Med J. 2015; 28:471.

79. Hestnes A, Stovner LJ, Husøy O, Følling I, Fougner KJ, Sjaastad O. Hormonal and biochemical disturbances in Down's syndrome. J Ment Defic Res. 1991; 35(Pt 3):179–93.

80. Hawli Y, Nasrallah M, El-Hajj Fuleihan G. Endocrine and musculoskeletal abnormalities in patients with Down syndrome. Nat Rev Endocrinol. 2009; 5:327–34.